Compare Citius Pharmaceuticals Inc (CTXR) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Ralph Lauren Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Ralph Lauren Corp trades at $374.08 (market cap $21.96B). The key difference: Ralph Lauren Corp is far larger — about 1500× Citius Pharmaceuticals Inc's market cap, and Ralph Lauren Corp pays a 1.01% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | RL | |
|---|---|---|
Market Cap | $14.64M | $21.96B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $414.25 |
52-Week Low | $0.53 | $283.34 |
Enterprise Value | $10.86M | $22.90B |
Dividend Yield | — | 1.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Ralph Lauren (RL) trades at $374.49, down 5.17% on the day, showing bearish technical momentum despite strong fundamentals. The company demonstrates robust financial performance with consistent earnings beats, including Q1 2026 EPS of $2.80 beating expectations of $2.55. Revenue growth accelerated to $7.08 billion in 2025 with net income margin expanding to 10.49%. Analyst consensus remains strongly bullish with 66% buy ratings and a $446.25 price target representing 19% upside potential.
The stock presents a compelling growth opportunity with strong brand momentum and digital expansion driving performance, though premium valuation metrics and technical bearish signals warrant caution. Key risks include macroeconomic sensitivity and competitive pressures in the apparel sector, while institutional sentiment remains positive given the company's execution on its Next Great Chapter strategy and Asia growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
